Sawai Group Holdings Co., Ltd. (4887.T)
JPY 2052.5
(2.22%)
JPY 2052.5
(2.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 36.87 Billion JPY | 5.91% |
| 2022 | 33.93 Billion JPY | 286.54% |
| 2021 | -18.7 Billion JPY | -150.67% |
| 2020 | 37.25 Billion JPY | -17.24% |
| 2019 | 45 Billion JPY | 5.85% |
| 2018 | 42.47 Billion JPY | 15.69% |
| 2017 | 35.61 Billion JPY | 14.27% |
| 2016 | 31.47 Billion JPY | 5.42% |
| 2015 | 30.52 Billion JPY | 13.85% |
| 2014 | 26.41 Billion JPY | 10.27% |
| 2013 | 24.19 Billion JPY | 13.85% |
| 2012 | 22.04 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 9.56 Billion JPY | 64.01% |
| 2023 FY | - JPY | 5.91% |
| 2023 Q3 | 10.99 Billion JPY | 2.56% |
| 2023 Q4 | 5.95 Billion JPY | -45.84% |
| 2023 Q1 | 9.29 Billion JPY | 30.78% |
| 2023 Q2 | 10.72 Billion JPY | 15.38% |
| 2022 Q4 | 7.1 Billion JPY | -30.57% |
| 2022 Q3 | 10.23 Billion JPY | 22.09% |
| 2022 Q2 | 8.38 Billion JPY | -8.42% |
| 2022 Q1 | 9.15 Billion JPY | 116.37% |
| 2022 FY | - JPY | 286.54% |
| 2021 Q4 | -55.9 Billion JPY | -482.45% |
| 2021 Q1 | 12.86 Billion JPY | 179.61% |
| 2021 FY | - JPY | -150.67% |
| 2021 Q3 | 14.61 Billion JPY | 50.27% |
| 2021 Q2 | 9.72 Billion JPY | -24.38% |
| 2020 Q3 | 13.37 Billion JPY | 13.75% |
| 2020 Q1 | 11.48 Billion JPY | 94.43% |
| 2020 FY | - JPY | -17.24% |
| 2020 Q4 | 4.6 Billion JPY | -65.6% |
| 2020 Q2 | 11.75 Billion JPY | 2.41% |
| 2019 Q4 | 5.9 Billion JPY | -55.6% |
| 2019 Q3 | 13.3 Billion JPY | 24.34% |
| 2019 Q2 | 10.69 Billion JPY | -18.81% |
| 2019 FY | - JPY | 5.85% |
| 2019 Q1 | 13.17 Billion JPY | 60.03% |
| 2018 Q2 | 10.47 Billion JPY | -7.24% |
| 2018 Q3 | 12.27 Billion JPY | 17.17% |
| 2018 Q1 | 11.29 Billion JPY | 65.43% |
| 2018 FY | - JPY | 15.69% |
| 2018 Q4 | 8.23 Billion JPY | -32.91% |
| 2017 FY | - JPY | 14.27% |
| 2017 Q1 | 7.51 Billion JPY | 54.21% |
| 2017 Q4 | 6.82 Billion JPY | -32.35% |
| 2017 Q3 | 10.08 Billion JPY | 19.93% |
| 2017 Q2 | 8.41 Billion JPY | 11.94% |
| 2016 Q2 | 7.46 Billion JPY | -2.19% |
| 2016 Q4 | 4.87 Billion JPY | -41.11% |
| 2016 Q1 | 7.62 Billion JPY | 35.83% |
| 2016 Q3 | 8.27 Billion JPY | 10.91% |
| 2016 FY | - JPY | 5.42% |
| 2015 FY | - JPY | 13.85% |
| 2015 Q4 | 5.61 Billion JPY | -38.89% |
| 2015 Q3 | 9.18 Billion JPY | 33.01% |
| 2015 Q2 | 6.9 Billion JPY | -11.62% |
| 2015 Q1 | 7.81 Billion JPY | 64.39% |
| 2014 Q4 | 4.75 Billion JPY | -43.52% |
| 2014 Q3 | 8.42 Billion JPY | 28.06% |
| 2014 Q2 | 6.57 Billion JPY | 4.81% |
| 2014 Q1 | 6.27 Billion JPY | 87.86% |
| 2014 FY | - JPY | 10.27% |
| 2013 Q2 | 5.44 Billion JPY | -19.64% |
| 2013 Q1 | 6.78 Billion JPY | 64.19% |
| 2013 Q4 | 3.33 Billion JPY | -57.71% |
| 2013 FY | - JPY | 13.85% |
| 2013 Q3 | 7.89 Billion JPY | 44.89% |
| 2012 Q4 | 4.13 Billion JPY | -40.98% |
| 2012 Q2 | 4.86 Billion JPY | 0.0% |
| 2012 FY | - JPY | 0.0% |
| 2012 Q3 | 6.99 Billion JPY | 43.94% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | -512.407% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 95.784% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 113.119% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 80.25% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -6357.935% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | -1.607% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | -200.587% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 64.238% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -2751.74% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | -101.052% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | -310.933% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -904.714% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -2528.154% |
| Tsumura & Co. | 30.77 Billion JPY | -19.826% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | -96.971% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | -599.545% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | -3.762% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | -435.789% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | -110.443% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | -258.129% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 1083.28% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | -388.19% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 5264.286% |
| MedRx Co., Ltd | -884.51 Million JPY | 4268.721% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | -566.024% |
| Solasia Pharma K.K. | -635 Million JPY | 5906.772% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 1653.252% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | -302.412% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 6950.038% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | -42.67% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -622.767% |